Advertisement
Screener

Rein Therapeutics, Inc. (RNTX) Construction in Progress Expenditures Incurred but Not yet Paid

Rein Therapeutics, Inc. Construction in Progress Expenditures Incurred but Not yet Paid

Rein Therapeutics, Inc. (RNTX) reported Construction in Progress Expenditures Incurred but Not yet Paid of $6.62 million for the 9-month period ending 2018-09-30, per its 10-Q filed 2018-11-07.

Discontinued › Cash Flow › Other Cash Flow Items

us-gaap:ConstructionInProgressExpendituresIncurredButNotYetPaid · last filed 2018-11-07

  • Rein Therapeutics, Inc. construction in progress expenditures incurred but not yet paid for the quarter ending 2018-09-30 was $2.68M.
Period endConstruction in Progress Expenditures Incurred but Not yet Paid 3 monthConstruction in Progress Expenditures Incurred but Not yet Paid 6 monthConstruction in Progress Expenditures Incurred but Not yet Paid 9 month
2018-09-30$2.68M
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07
$6.62M
10-Q · filed 2018-11-07
2018-06-30$3.94M
10-Q · filed 2018-08-07

Similar stocks

Stock NameCountryMarket CapPE Ratio
HYPERION DEFI, INC. (HYPD)United States$0.065B
XBiotech Inc. (XBIT)United States$0.066B-1.56
Skye Bioscience, Inc. (SKYE)United States$0.061B-0.48
CalciMedica, Inc. (CALC)United States$0.061B-1.42
TALPHERA, INC. (TLPH)United States$0.060B
Boundless Bio, Inc. (BOLD)United States$0.059B-0.88
NOMAD POWER SOLUTIONS, INC. (NMAD)United States$0.058B
Connect Biopharma Holdings Ltd (CNTB)$0.069B-2.17
Yarrow Bioscience, Inc. (YARW)United States$0.070B
Annovis Bio, Inc. (ANVS)United States$0.056B-1.58